Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Cezary Wójcik. (2017) Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgraduate Medicine 129:8, pages 801-810.
Read now
Read now
Alessandro Colletti, Giuseppe Derosa & Arrigo FG Cicero. (2016) Retargeting the management of hypercholesterolemia – focus on evolocumab. Therapeutics and Clinical Risk Management 12, pages 1365-1376.
Read now
Read now
Maria Drakopoulou, Konstantinos Toutouzas, Konstantinos Stathogiannis, Andreas Synetos, George Trantalis & Dimitrios Tousoulis. (2016) Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy 14:11, pages 1263-1271.
Read now
Read now
Ilaria Giunzioni & Hagai Tavori. (2015) New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vascular Health and Risk Management 11, pages 493-501.
Read now
Read now
Arrigo FG Cicero, Alessandro Colletti & Claudio Borghi. (2015) Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Design, Development and Therapy 9, pages 3073-3082.
Read now
Read now
Arrigo FG Cicero, Elisa Tartagni & Sibel Ertek. (2014) Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opinion on Drug Safety 13:8, pages 1023-1030.
Read now
Read now
Articles from other publishers (12)
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, Irina I. Nadelyaeva, Nikita A. Gutyrchik & Alexander N. Orekhov. (2023) Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis. Biomedicines 11:2, pages 503.
Crossref
Crossref
Jin-Taek Hwang, Eunji Choi, Hyo-Kyoung Choi, Jae-Ho Park & Min-Yu Chung. (2021) The Cholesterol-Lowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1α-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells. Foods 10:2, pages 408.
Crossref
Crossref
О.А. Гальцова & А.Г. Захаренко. (2020) Hypolipidemic Pharmacotherapy from the Latest Recommendations. Рецепт:1, pages 97-107.
Crossref
Crossref
Hui-xian Yang, Min Zhang, Shi-yin Long, Qin-hui Tuo, Ying Tian, Jian-xiong Chen, Cai-ping Zhang & Duan-fang Liao. (2020) Cholesterol in LDL receptor recycling and degradation. Clinica Chimica Acta 500, pages 81-86.
Crossref
Crossref
航鹰 应. (2019) PCSK9 Monoclonal Antibody: 12 Years, from Basic Research to Clinical Application. Advances in Clinical Medicine 09:11, pages 1255-1260.
Crossref
Crossref
Cosimo Andrea Stamerra, Paolo Di Giosia, Paolo Giorgini, Martina De Feo, Davide Grassi, Claudio Ferri & Amirhossein Sahebkar. (2018) Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence. Journal of Neuroscience Research 96:5, pages 762-764.
Crossref
Crossref
Naveed Sattar, Peter P. Toth, Dirk J. Blom, Michael J. Koren, Handrean Soran, Magdalena Uhart, Mary Elliott, Marcoli Cyrille, Ransi Somaratne & David Preiss. (2017) Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus. The American Journal of Cardiology 120:9, pages 1521-1527.
Crossref
Crossref
Ni-ya He, Qing Li, Chun-yan Wu, Zhong Ren, Ya Gao, Li-hong Pan, Mei-mei Wang, Hong-yan Wen, Zhi-sheng Jiang, Zhi-han Tang & Lu-shan Liu. (2017) Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. Acta Pharmacologica Sinica 38:3, pages 301-311.
Crossref
Crossref
Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan & Cheng-Yun Liu. (2017) The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. European Journal of Internal Medicine 38, pages 52-60.
Crossref
Crossref
Dirk J. Blom, Michael J. Koren, Eli Roth, Maria Laura Monsalvo, C. Stephen Djedjos, Patric Nelson, Mary Elliott, Scott M. Wasserman, Christie M. Ballantyne & Rury R. Holman. (2017) Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism 19:1, pages 98-107.
Crossref
Crossref
Salvatore V. Pizzo, Roger L. Lundblad & Monte S. Willis. 2016. Proteolysis in the Interstitial Space. Proteolysis in the Interstitial Space
1
42
.
Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J Feinstein, Arman Qamar, Parag H Joshi, Kristopher J Swiger, Kathleen Byrne, Renato Quispe, Steven R Jones, Roger S Blumenthal & Seth S Martin. (2016) PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab. Future Cardiology 12:2, pages 139-148.
Crossref
Crossref